Clinical trials: Metastatic Progressive Breast Cancer
Estrogen Receptor Positive Breast Cancer
Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy
To determine the safety and tolerability of orally administered hydroxychloroquine with hormonal therapy. To assess the response rate of hydroxychloroquine in combination with hormonal therapy.
- Trial name
- ABC01 (NCT02414776)
- Testing
- hydroxychloroquine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Western Regional Medical Center
Metastatic ER+ Her2- Breast Cancer, Postmenopausal
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
The purpose of this study is to assess the safety and efficacy of oral abiraterone acetate plus oral prednisone and oral abiraterone acetate plus oral prednisone plus oral exemestane, each compared with oral exemestane alone, in…
- Trial name
- NCT01381874
- Testing
- Exemestane, Abiraterone acetate + Prednisone/ Prednisolone + Exemestane, Abiraterone acetate + Prednisone or Prednisolone
- Where
- 81 sites in United States, Belgium and 10 more
- Volunteers
- 297 people
- Sponsor
- Janssen Research & Development, LLC
Cancer
Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Trial name
- NCT00003538
- Testing
- graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Breast Cancer, Advanced Breast Cancer
Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment
The purpose of the study is to demonstrate clinical efficacy of the investigational trifunctional bispecific antibody ertumaxomab for treatment of patients with HER-2/neu 1+ or 2+ (FISH-) expressing advanced or metastatic breast…
- Trial name
- NCT00452140
- Testing
- ertumaxomab
- Where
- 5 sites in Austria, France and 3 more
- Volunteers
- 40 people
- Sponsor
- Neovii Biotech
Metastatic Breast Cancer
Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
The purpose of this study is to determine the recommended phase 2 dose and overall safety and tolerability of TRC105 when given in combination with capecitabine for the treatment of patients with progressive or recurrent…
- Trial name
- TRC105 (NCT01326481)
- Testing
- TRC105, Capecitabine
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Breast Cancer, Neoplasm Metastasis
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
Primary Objectives: 1. To identify the optimal dose and pharmacokinetics of RAD001 in combination with trastuzumab in a Phase I trial 2.
- Trial name
- NCT00317720
- Testing
- Trastuzumab, RAD001
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
This randomized, 3-arm, multicenter, phase III study will evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) with pertuzumab or trastuzumab emtansine (T-DM1) with pertuzumab-placebo (blinded for pertuzumab), versus…
- Trial name
- NCT01120184
- Testing
- docetaxel, paclitaxel, pertuzumab
- Where
- 257 sites in United States, Argentina and 36 more
- Volunteers
- 1,095 people
- Sponsor
- Hoffmann-La Roche
Brain Cancer Metastatic, CMV Viremia
Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection
This is a phase II trial with an initial safety lead-in evaluating the efficacy, safety, neurocognitive, and quality-of-life outcomes of anti-cytomegalovirus (CMV) therapy and standard-of-care (SOC) in patients with anti-human…
- Trial name
- NCT07383649
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The Methodist Hospital Research Institute
HER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
This phase III, double-blind, placebo-controlled multinational study will assess the combination everolimus, vinorelbine, and trastuzumab compared to the combination vinorelbine and trastuzumab with respect to progressive-free…
- Trial name
- BOLERO-3 (NCT01007942)
- Testing
- everolimus, vinorelbine, trastuzumab
- Where
- 161 sites in United States, Argentina and 19 more
- Volunteers
- 569 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases
Palbociclib and Pembrolizumab In Central Nervous System Metastases
This research study is studying This research study is studying the efficacy and safety of the following study drugs as a possible treatment for recurrent central nervous system (CNS) metastases: Palbociclib alone (Cohort 1) The…
- Conditions
- Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain Metastases
- Trial name
- NCT02896335
- Testing
- Palbociclib, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Massachusetts General Hospital
Metastatic Breast Cancer, Breast Cancer
Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
The purpose of this research study is to determine how well the combination of bevacizumab and carboplatin works in treating breast cancer that has spread to the brain.
- Conditions
- Metastatic Breast Cancer, Breast Cancer, Progressive Breast Cancer
- Trial name
- NCT01004172
- Testing
- carboplatin, bevacizumab, herceptin
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Dana-Farber Cancer Institute
Postmenopausal, Metastatic Breast Cancer
A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors
Metastatic breast cancer (MBC) remains an incurable disease and despite an improvement of the effect of systemic treatments. After relapse on first-line non-steroidal aromatase inhibitor, current clinical practice and treatment…
- Trial name
- OLYMPE (NCT02322853)
- Testing
- Tamoxifen, Ralimetinib (LY2228820 dimesylate)
- Where
- 14 sites in France
- Volunteers
- 8 people
- Sponsor
- Centre Francois Baclesse
Breast Cancer, Estrogen Receptor-Positive Breast Cancer
Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer
The purpose of this study is to evaluate the safety and efficacy of entinostat in combination with exemestane in the treatment of advanced breast cancer.
- Conditions
- Breast Cancer, Estrogen Receptor-Positive Breast Cancer, Breast Cancer, Estrogen Receptor-Positive, ER+ Breast Cancer
- Trial name
- ENCORE301 (NCT00676663)
- Testing
- entinostat, exemestane
- Where
- 38 sites in United States, Canada and 3 more
- Volunteers
- 130 people
- Sponsor
- Syndax Pharmaceuticals
Breast Cancer
Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00103233
- Testing
- trastuzumab, vinorelbine tartrate
- Sponsor
- SWOG Cancer Research Network
Male Breast Cancer, Recurrent Breast Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer
This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with progressive stage IV breast cancer.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00132002
- Testing
- vorinostat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer, Brain Metastases
Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer
Objectives: Primary - Determine the maximum tolerated dose (MTD) and evaluate the dose limiting toxicities (DLT) of combining lapatinib and temozolomideSecondary - Obtain preliminary information on the clinical anti-tumor…
- Conditions
- Metastatic Breast Cancer, Brain Metastases, HER2 Positive
- Trial name
- LAPTEM (NCT00614978)
- Testing
- lapatinib and temozolomide
- Where
- Belgium
- Volunteers
- 18 people
- Sponsor
- Jules Bordet Institute
Breast Cancer
S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop tumor cells from dividing so…
- Trial name
- NCT00087152
- Testing
- Capecitabine, Imatinib mesylate
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment
RATIONALE: Caspofungin acetate or amphotericin B liposomal may be effective in preventing or controlling fever and neutropenia caused by chemotherapy, bone marrow transplantation, or peripheral stem cell transplantation.
- Trial name
- NCT00008359
- Testing
- caspofungin acetate, liposomal amphotericin B
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Breast Cancer, Advanced Breast Cancer
Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy
This study has the purpose to demonstrate clinical efficacy of the investigational new drug ertumaxomab in patients with human epidermal growth factor receptor-2 (HER-2/neu) overexpressing (3+ or 2+ with a positive Fluorescence…
- Trial name
- NCT00522457
- Testing
- ertumaxomab
- Where
- 5 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- Neovii Biotech
Breast Cancer, Metastases
Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer
The purpose of this clinical trial is to determine if RPR109881 is a better treatment than capecitabine (Xeloda) for advanced breast cancer in patients that no longer benefit from docetaxel and/or paclitaxel.
- Trial name
- NCT00081796
- Testing
- larotaxel (RPR109881, XRP9881), capecitabine
- Where
- 187 sites in United States, Argentina and 24 more
- Volunteers
- 438 people
- Sponsor
- Sanofi